Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial
Bristol-Myers Squibb
Takayuki Yoshino; Eiji Oki; Toshihiro Misumi; Masahito Kotaka; Dai Manaka; Tetsuya Eto; Junichi Hasegawa; Akinori Takagane; Masato Nakamura; Takeshi Kato; Yoshinori Munemoto; Fumitaka Nakamura; Hiroyuki Bando; Hiroki Taniguchi; Yasuhiro Sakamoto; Manabu Shiozawa; Masayasu Nishi; Tetsuya Horiuchi; Hisakazu Yamagishi; Junichi Sakamoto; Tsunekazu Mizushima; Atsushi Ohtsu; Masaki Mori